Plain-English translation of NCT07307586 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a medication called alongside two other standard treatments to see which approach works best for people with chronic hepatitis B. The study follows a novel idea: combining antiviral power (killing the virus) with immune activation (boosting your body's own defenses). Researchers will track your virus levels, liver health, and immune response over time to measure how well this treatment works.
Chronic hepatitis B is a serious long-term infection, and many patients don't achieve a true cure with existing treatments. This trial explores whether adding immune activation to antiviral therapy could offer patients a better chance at clinical cure rather than just managing the disease.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to take one of three medications: , , or interferon alfa-2a. Throughout the study, you'll have regular clinic visits where doctors will monitor your blood work—specifically your virus levels, liver function tests, and immune cell activity—to see how well the medication is working. The study involves careful tracking over time to precisely measure whether this new treatment approach can help you achieve clinical cure.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
China